Provided by:
Penn Medicine
Continuing Medical and Interprofessional Education

**Radiation Oncology Weekly Chart Rounds 2025-2026**

## Radiation Oncology Weekly Chart Rounds 2025-2026 - 11/20/2026
**November 20, 2026**
**12:00 PM - 1:00 PM**
**Radiation Oncology, TRC-2 West Conference Room**

**Target Audience**
This program has been designed for RADIATION ONCOLOGY

**Series Educational Objectives**
After participating in this regularly scheduled series, participants should be able to:
1 Discuss differential diagnosis in complex oncology cases
2 Describe how to apply targeted dosing strategies
3 Discuss how to implement into practice recommended guidelines on patient care

**Accreditation**
In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Designation of Credit:**

**Physicians**: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is for **1.00** contact hours.

**Pharmacists: This activity is not approved for pharmacy contact hours.**

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

**Approved for (PSRM) patient safety/risk management designation**

**Acknowledgement of Commercial Support*:** None

**For more information, please contact**
**Lora Furman, Atalya Koss**
**(215) 490-8599, (445) 326-5295**
**lora.furman@pennmedicine.upenn.edu, atalya.koss@pennmedicine.upenn.edu**

**Check your transcript online at** https://upenn.cloud-cme.com

Penn Medicine
Continuing Medical and Interprofessional Education

**Disclosure of Relevant Financial Relationships and Unapproved Uses of Products**

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|---|---|---|
| Michelle Alonso-Basanta, MD | Other Planning Committee Member | Nothing to disclose - 05/19/2026 |
| Edgar Ben-Josef, MD | Other Planning Committee Member | Nothing to disclose - 05/19/2026 |
| Anish A Butala, MD | Other Planning Committee Member | Paid consultant-2nd.MD - 09/01/2026 |
| Erin Davis, CRNP RN | Nurse Planner | Nothing to disclose - 06/22/2026 |
| Steven j Feigenberg, MD | Other Planning Committee Member | Honoraria-Astra Zeneca Pharmaceuticals (Relationship has ended)\|Paid consultant-Johnson & Johnson\|Honoraria-Varian Medical Systems - 05/20/2026 |
| Arun Goel, MD | Other Planning Committee Member | Consulting Fee-Boston Scientific Corporation - 07/20/2026 |
| Benjamin Goldsmith, MD | Other Planning Committee Member | Nothing to disclose - 06/22/2026 |
| John N Lukens, MD | Other Planning Committee Member | Nothing to disclose - 07/10/2026 |
| Suneel Nagda, MD | Course Director, Faculty | Nothing to disclose - 11/08/2026 |
| Eric Ojerholm, MD | Other Planning Committee Member | Nothing to disclose - 07/09/2026 |
| John Plastaras, MD | Other Planning Committee Member | Nothing to disclose - 06/03/2026 |
| Neil Taunk, MD, MS | Other Planning Committee Member | Consulting Fee-Boston Scientific Corporation\|Consulting Fee-Point BioPharma (Relationship has ended)\|Grant or research support-Varian Medical Systems |

| | | |
|---|---|---|
| | | (Relationship has ended)\|Grant or research support-Therapanacea AI (Relationship has ended)\|Grant or research support-Bristol-Myers Squibb\|Grant or research support-Novartis / Amgen - 07/21/2026 |
| Kevin Teo, PhD | Other Planning Committee Member | Nothing to disclose - 06/19/2026 |
| Patrick Tripp, MD | Co-Director | Nothing to disclose - 06/10/2026 |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected